Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484287 | 0.78 | GPR84 (0.45) | IDO1GPR84LPLLIPG | |
| SCHEMBL20595125 | 0.76 | IMPDH2 (0.30) | — | |
| SCHEMBL30182153 | 0.76 | HTR1D (0.42) | IDO1 | |
| SCHEMBL29977632 | 0.74 | LPL (0.38) | JAK2BTKLPLLIPG | |
| SCHEMBL14816525 | 0.74 | LPL (0.38) | JAK2BTKLPLLIPG | |
| SCHEMBL1477757 | 0.74 | LPL (0.38) | JAK2BTKLPLLIPG | |
| SCHEMBL25508360 | 0.72 | GPR84 (0.45) | GPR84LPLLIPG | |
| SCHEMBL16727198 | 0.71 | GPR84 (0.44) | IDO1EGFRGPR84 | |
| SCHEMBL29750587 | 0.71 | LPL (0.33) | LPLLIPG | |
| SCHEMBL3197383 | 0.71 | CDK4 (0.49) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | IDO1 4308/4885EGFR 1111/4885JAK2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.